Japan’s Ministry of Health, Labour and Welfare Approves Gilead’s Epclusa® (Sofosbuvir/Velpatasvir)
Gilead Sciences, Inc. (NASDAQ: GILD) announced today that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved Epclusa® (sofosbuvir 400mg/velpatasvir 100mg), a once-daily treatment for adults with chronic hepatitis C virus (HCV) infection with decompensated cirrhosis, and for patients with chronic HCV infection without cirrhosis or with compensated cirrhosis who have had prior treatment with a direct-acting antiviral therapy (DAA).
Until now, no treatment option has been available in Japan for the treatment of chronic HCV infection with decompensated cirrhosis, and there have been limited treatment options for patients with chronic HCV infection who have had prior treatment with a DAA. Epclusa offers a new option for both of these difficult-to-treat patient populations.
“Gilead has continued to develop new HCV therapies to help ensure all people with HCV have a chance at cure and, ultimately, to help eliminate the disease worldwide,” said John McHutchison, AO, MD, Chief Scientific Officer, Head of Research and Development, Gilead Sciences. “In Japan, people with HCV who have decompensated cirrhosis or who did not achieve cure with prior HCV treatment, had few to no treatment options until now. We are pleased to offer a new treatment option to address this important clinical need in Japan.”
Epclusa is a combination treatment that contains sofosbuvir, an NS5B polymerase inhibitor that was approved in Japan as Sovaldi ® 400 mg tablets in March 2015, and velpatasvir, an active ingredient that inhibits NS5A.
In Japan, Epclusa is indicated for the suppression of viremia in patients with chronic HCV infection. Patients with chronic HCV infection with decompensated cirrhosis should take one tablet of Epclusa once daily for 12 weeks, and patients with chronic HCV infection without cirrhosis or with compensated cirrhosis that have had prior DAA treatment experience should take one tablet of Epclusa once daily for 24 weeks, in combination with ribavirin (RBV).
The approval of Epclusa in Japan is supported by data from a Phase 3 clinical study in Japanese patients with HCV infection with decompensated cirrhosis (Study GS-US-342-4019) in which 92 percent (47/51) of patients who received Epclusa for 12 weeks achieved SVR12 (defined as undetectable HCV RNA 12 weeks after completing therapy). Patients who achieve SVR12 are considered cured of HCV. In a separate Phase 3 clinical study in Japanese patients with genotype 1 or 2 HCV infection who failed prior DAA therapy (Study GS-US-342-3921), 97 percent (58/60) of patients who received Epclusa with RBV for 24 weeks achieved SVR12. In both studies, Epclusa was generally well tolerated. Among patients receiving Epclusa for 12 weeks in GS-US-342-4019, the most common adverse event was nasopharyngitis and no patient discontinued treatment with Epclusa due to adverse events. Among patients receiving Epclusa with RBV for 24 weeks in GS-US-342-3921, the most common adverse events were viral upper respiratory tract infection and anemia and 3.3 percent of patients discontinued Epclusa due to adverse events.
The US Prescribing Information for Epclusa contains a Boxed Warning regarding the risk of hepatitis B virus reactivation in HCV/HIV co-infected patients. See below for US Important Safety Information and Indication.
EPCLUSA US Important Safety Information
BOXED WARNING: RISK OF HEPATITIS B VIRUS REACTIVATION IN HCV/HBV COINFECTED PATIENTS
- Test all patients for evidence of current or prior hepatitis B virus (HBV) infection before initiating treatment with EPCLUSA. HBV reactivation has been reported in HCV/HBV coinfected patients who were undergoing or had completed treatment with HCV direct acting antivirals (DAAs) and were not receiving HBV antiviral therapy. Some cases have resulted in fulminant hepatitis, hepatic failure, and death. Cases have been reported in patients who are HBsAg positive, in patients with serologic evidence of resolved HBV, and also in patients receiving certain immunosuppressant or chemotherapeutic agents; the risk of HBV reactivation associated with treatment with HCV DAAs may be increased in patients taking these other agents. Monitor HCV/HBV coinfected patients for hepatitis flare or HBV reactivation during HCV treatment and post-treatment follow-up. Initiate appropriate patient management for HBV infection as clinically indicated.
- If EPCLUSA is used in combination with RBV, all contraindications, warnings and precautions, in particular pregnancy avoidance, and adverse reactions to RBV also apply. Refer to RBV prescribing information.
Warnings and Precautions
- Serious Symptomatic Bradycardia When Coadministered with Amiodarone: Amiodarone is not recommended for use with EPCLUSA due to the risk of symptomatic bradycardia, particularly in patients also taking beta blockers or with underlying cardiac comorbidities and/or with advanced liver disease. A fatal cardiac arrest was reported in a patient taking amiodarone who was coadministered a sofosbuvir containing regimen. In patients without alternative, viable treatment options, cardiac monitoring is recommended. Patients should seek immediate medical evaluation if they develop signs or symptoms of bradycardia.
- Risk of Reduced Therapeutic Effect Due to Concomitant Use of EPCLUSA with P-gp Inducers and/or Moderate to Potent Inducers of CYP2B6, CYP2C8 or CYP3A4: Rifampin, St. John’s wort, and carbamazepine are not recommended for use with EPCLUSA as they may significantly decrease sofosbuvir and/or velpatasvir plasma concentrations.
- The most common adverse reactions (≥10%, all grades) with EPCLUSA were headache and fatigue; and when used with RBV in decompensated cirrhosis were fatigue, anemia, nausea, headache, insomnia, and diarrhea.
- Coadministration of EPCLUSA is not recommended with topotecan due to increased concentrations of topotecan.
- Coadministration of EPCLUSA is not recommended with proton-pump inhibitors, oxcarbazepine, phenobarbital, phenytoin, rifabutin, rifapentine, efavirenz, and tipranavir/ritonavir due to decreased concentrations of sofosbuvir and/or velpatasvir.
- Consult the full Prescribing Information for EPCLUSA for more information on potentially significant drug interactions, including clinical comments.
EPCLUSA is indicated for the treatment of adults with chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5, or 6 infection without cirrhosis or with compensated cirrhosis and in combination with ribavirin for those with decompensated cirrhosis.
About Gilead Sciences
Gilead Sciences is a research-based biopharmaceutical company that discovers, develops, and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California. For more information on Gilead Sciences, please visit the company’s website at www.gilead.com.
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties, and other factors, including the risk that physicians may not see the benefits of prescribing Epclusa for the treatment of chronic HCV infection and the possibility of unfavorable results from ongoing and additional clinical studies involving Epclusa. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. These and other risks are described in detail in Gilead’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2018, as filed with the U.S. Securities and Exchange Commission. All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation to update any such forward-looking statements.
US Full Prescribing Information for Epclusa, including BOXED WARNING, is available at www.gilead.com .
Epclusa ® and Sovaldi ® are registered trademarks of Gilead Sciences, Inc., or its related companies.
For more information on Gilead Sciences, please visit the company’s website at www.gilead.com , follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.
Sung Lee, Investors
+1 (650) 524-7792
Seiko Noma, Media Japan
Arran Attridge, Media US
+1 (650) 425-8975
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
RIBOMIC Announces Positive Top-Line Results from the Phase 1/2a Clinical Trial of RBM-007 (SUSHI Study) in Subjects with Wet Age-Related Macular Degeneration17.6.2019 16:15:00 EEST | Tiedote
RIBOMIC, Inc., a clinical stage pharmaceutical company specializing in aptamer therapeutics and traded on the Mothers Market of the Tokyo Stock Exchange (Code Number: 4591), today announced positive top-line results from its SUSHI study, Phase 1/2a single ascending dose clinical study of RBM-007, anti-FGF2 aptamer, in nine subjects with wet Age-Related Macular Degeneration (wet AMD). SUSHI study achieved the primary endpoint of safety and tolerability, and also demonstrated efficacy trends in favor of RBM-007. Subjects recruited for the SUSHI Study had wet AMD that was poorly responsive to previous intravitreal anti-VEGF therapy. Through the 56-Day exit visit, excluding one uncompleted case in the last cohort, single dose of RBM-007 demonstrated no dose-limiting toxicities, no systemic or ocular serious adverse events. One subject in Cohort 3 showed anterior inflammation, which was resolved after one day of topical prednisolone treatment. Rescue treatment with anti-VEGF therapy was ava
ECB Chooses SIA And Colt for the Access Network to the Eurosystem’s Payments, Securities and Collateral Infrastructures17.6.2019 16:00:00 EEST | Tiedote
SIA, in partnership with Colt Technology Services, has won a tender commissioned by the European Central Bank for the provisioning of connectivity services allowing European central and commercial banks, central depositories, automated clearing houses and other payment service providers to connect directly to Eurosystem market infrastructures through a single access interface (Eurosystem Single Market Infrastructure Gateway - ESMIG). Thanks to the concession granted to SIA and Colt as Network Service Providers for the ESMIG, starting from November 2021, all the key organisations in the European financial system will be able to access the platform for the settlement of large-value payments TARGET2, the instant payments settlement service TIPS, the securities settlement platform TARGET2-Securities (T2S), the Eurosystem Collateral Management System (ECMS) and possibly other new services and applications. ESMIG is a fundamental component in the implementation of the TARGET2 and TARGET2-Sec
WPP and iHeartMedia Launch ‘Project Listen’17.6.2019 15:00:00 EEST | Tiedote
iHeartMedia, America’s leading audio company, and WPP, the creative transformation company, today announced the launch of Project Listen to develop next-generation insights, planning and creative capabilities in audio. The two companies will help brands better engage with consumers and win across all audio platforms: broadcast radio, digital streaming, podcasts, smart speakers and live events. Consumer listening is at an all-time high, according to new iHeartMedia research. The study shows consumers say they are listening to audio content for an average of 17 hours a week, with millennials and younger generations listening the most. This ramp up in listening is the direct result of the rapid growth of digital streaming, podcasts, smart speakers and airpods, on top of the massive and consistent scale of broadcast radio. The new partnership comprises: Creative Audio Studio – Audio will be pushed higher on the agendas of creatives and media strategists with the launch of a new studio at G
GENECAST Launches BRAF Mutation Test Kits with the Highest Detection Sensitivity 0.0001%17.6.2019 15:00:00 EEST | Tiedote
GENECAST, cancer diagnostics company through liquid biopsy, today announced the launch of ADPSTM BRAF, EGFR, JAK2 mutation test kits with the highest detection sensitivity for Research Use Only (RUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190617005007/en/ GENECAST, cancer diagnostics company through liquid biopsy, launched ADPSTM BRAF, EGFR, JAK2 mutation test kits with the highest detection sensitivity for Research Use Only (RUO). ADPS(TM) BRAF Mutation Test Kit (RUO) (Photo: Business Wire) Especially ADPSTM BRAF mutation test kit has 0.0001% detection sensitivity which is 100 times higher than any other products, as well as EGFR and JAK2 mutation kits have the high detection sensitivity of 0.01%. Detection sensitivity is the most important indicator of determining the accuracy of liquid biopsy. According to Butler TM, Spellman PT, Gray J. Circulating-tumor DNA as an early detection and diagnostic tool. Curr Opin G
AB InBev Rolls Out PureDraught™ System to Keep Beer Fresh Longer, Reduce Carbon Footprint17.6.2019 15:00:00 EEST | Tiedote
AB InBev, through its Global Innovation and Technology Center (GITEC), is introducing PureDraught™, a one-way, polymer keg system that keeps beer fresher up to four times longer than a traditional steel keg and reduces the carbon footprint of shipping beer – all while offering more versatility and variety for bar and restaurant owners. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190617005244/en/ PureDraught™ comes in 6L, 12L and 18L sizes rather than the standard 30L or larger steel keg size, allowing for more flexibility and less wasted product by bar and restaurant owners. The kegs can be stored and dispensed from upright or on their side on a shelf, making them more versatile. (Photo: AB InBev GITEC) While beer delivered in a traditional steel keg is still preferred for beers produced and consumed locally or regionally, it produces a number of costly logistical and environmental issues that are magnified when shipped i
GSMA Debunks False Claims Threatening Future of 5G17.6.2019 14:04:00 EEST | Tiedote
The GSMA today hit out against false claims that 5G systems will harm other services, such as weather forecasting. The mobile industry has already demonstrated within leading international standards bodies that 5G can be used safely alongside other services, including weather sensing services, commercial satellite, radar and other applications using adjacent airwaves. The GSMA is confident that 5G services and weather sensing services can co-exist, and warns against giving credence to those claiming a negative impact from 5G networks on weather forecasting data. “5G and weather forecasts can and will co-exist – it’s ludicrous to suggest otherwise,” said Brett Tarnutzer, Head of Spectrum, GSMA. “To suggest that our 7-day forecast will go away with 5G is simply fake news. We cannot allow these scare tactics to prevent us from reaping the huge societal and economic benefits of 5G networks. We urge everyone to simply look at the facts and not get drawn in by misleading rhetoric.” The fact
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme